1800 EL CAMINO REAL, SUITE D, MENLO PARK, CA
Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights
2026 Annual Meeting of Stockholders Held by AN2 Therapeutics, Inc.
Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease
Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights
Annual Report to Security Holders
AN2 Therapeutics Enters $80 Million Open Market Sale Agreement with Jefferies
Stock Option Repricing Approved for Executive Officers at AN2 Therapeutics
Reports Fourth Quarter and Full Year End 2025 Financial Results and Recent Business and Scientific Highlights
Q2
Q1
FY 2025
Q3
FY 2024
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership